Monitoring Patients with Multiple Nevi

Dermatologic Clinics

Volumn 31, Issue 4, 2013, Pages 565-577

  Puig, Susana ^a   Malvehy, Josep ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Atypical mole syndrome; Dermoscopy; Follow up; Melanocytic nevi; Melanoma

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

AGE; ATYPICAL MOLE SYNDROME; CANCER PROGNOSIS; CDK4 GENE; CDKN2A GENE; CLINICAL FEATURE; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIGITAL DERMATOSCOPY; DISEASE SEVERITY; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; EXCISION; FAMILIAL CANCER; FAMILY HISTORY; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MEDICAL EXAMINATION; MELANOMA; MULTIPLE NEVUS; NEVUS; PATIENT COMPLIANCE; PATIENT MONITORING; PENETRANCE; PHOTOGRAPHY; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SELF EXAMINATION; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION; SKIN SELF EXAMINATION; SYNDROME; THREE DIMENSIONAL IMAGING; TOTAL BODY PHOTOGRAPHY;

ATYPICAL MOLE SYNDROME; DERMOSCOPY; FOLLOW-UP; MELANOCYTIC NEVI; MELANOMA;

DERMOSCOPY; HUMANS; NEVUS; NEVUS, PIGMENTED; RISK FACTORS; SKIN NEOPLASMS;

EID: 84884695210     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2013.06.004     Document Type: Review

References (77)

1. Breitbart E.W., Waldmann A., Nolte S., et al. Systematic skin cancer screening in Northern Germany. JAm Acad Dermatol 2012, 66(2):201-211. 10.1016/j.jaad.2010.11.016.
2. Bafounta M.L., Beauchet A., Aegerter P., et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 2001, 137(10):1343-1350.
3. Kittler H., Pehamberger H., Wolff K., et al. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002, 3(3):159-165.
4. Vestergaard M.E., Macaskill P., Holt P.E., et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008, 159(3):669-676. 10.1111/j.1365-2133.2008.08713.x.
5. Puig S., Argenziano G., Zalaudek I., et al. Melanomas that failed dermoscopic detection: a combined clinicodermoscopic approach for not missing melanoma. Dermatol Surg 2007, 33(10):1262-1273. 10.1111/j.1524-4725.2007.33264.x.
6. Carli P., De Giorgi V., Nardini P., et al. Melanoma detection rate and concordance between self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in Italy. Br J Dermatol 2002, 146(2):261-266.
7. Robinson J.K., Fisher S.G., Turrisi R.J. Predictors of skin self-examination performance. Cancer 2002, 95(1):135-146.
8. Nehal K.S., Oliveria S.A., Marghoob A.A., et al. Use of and beliefs about baseline photography in the management of patients with pigmented lesions: a survey of dermatology residency programmes in the United States. Melanoma Res 2002, 12(2):161-167.
9. Shriner D.L., Wagner R.F., Glowczwski J.R. Photography for the early diagnosis of malignant melanoma in patients with atypical moles. Cutis 1992, 50(5):358-362.
10. Kopf A.W., Salopek T.G., Slade J., et al. Techniques of cutaneous examination for the detection of skin cancer. Cancer 1995, 75(Suppl 2):684-690.
11. Kittler H., Pehamberger H., Wolff K., et al. Follow-upof melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. JAm Acad Dermatol 2000, 43(3):467-476.
12. Schiffner R., Schiffner-Rohe J., Landthaler M., et al. Long-term dermoscopic follow-up of melanocytic naevi: clinical outcome and patient compliance. Br J Dermatol 2003, 149(1):79-86.
13. Menzies S.W., Gutenev A., Avramidis M., et al. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001, 137(12):1583-1589.
14. Salerni G., Carrera C., Lovatto L., et al. Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. JAm Acad Dermatol 2011, 10.1016/j.jaad.2011.04.008.
15. Malvehy J., Puig S. Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin Dermatol 2002, 20(3):297-304.
16. Green W.H., Wang S.Q., Cognetta A.B. Total-body cutaneous examination, total-body photography, and dermoscopy in the care of a patient with xeroderma pigmentosum and multiple melanomas. Arch Dermatol 2009, 145(8):910-915.
17. Malvehy J., Puig S. Dermoscopy of skin lesions in two patients with xeroderma pigmentosum. Br J Dermatol 2005, 152(2):271-278. 10.1111/J.1365-2133.2004.06332.X.
18. Salerni G., Lovatto L., Carrera C., et al. Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. Arch Dermatol 2011, 147(5):549-555. 10.1001/archdermatol.2010.430.
19. Green A., MacLennan R., Siskind V. Common acquired naevi and the risk of malignant melanoma. Int J Cancer 1985, 35(3):297-300.
20. Swerdlow A.J., English J., MacKie R.M., et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986, 292(6535):1555-1559.
21. Ródenas J.M., Delgado-Rodríguez M., Farinas-Alvarez C., et al. Melanocytic nevi and risk of cutaneous malignant melanoma in southern Spain. Am J Epidemiol 1997, 145(11):1020-1029.
22. Bataille V., Grulich A., Sasieni P., et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998, 77(3):505-510.
23. Chang Y., Newton-Bishop J.A., Bishop D.T., et al. Apooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009, 124(2):420-428.
24. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41(1):28-44.
25. Rhodes A.R. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer?. Cancer 1995, 75(Suppl 2):613-636.
26. Rhodes A.R., Weinstock M.A., Fitzpatrick T.B., et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987, 258(21):3146-3154.
27. Clark W.H., Reimer R.R., Greene M., et al. Origin of familial malignant melanomas from heritable melanocytic lesions. "The B-K mole syndrome". Arch Dermatol 1978, 114(5):732-738.
28. Greene M.H., Clark W.H., Tucker M.A., et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985, 102(4):458-465.
29. Carli P., Massi D., Santucci M., et al. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case-control study. JAm Acad Dermatol 1999, 40(4):549-557.
30. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. JAm Acad Dermatol 2000, 42(5 Pt 1):705-722.
31. Soufir N., Avril M.F., Chompret A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998, 7(2):209-216.
32. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006, 66(20):9818-9828. 10.1158/0008-5472.CAN-06-0494.
33. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. JMed Genet 2007, 44(2):99-106. 10.1136/jmg.2006.043802.
34. Puig S., Ruiz A., Castel T., et al. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet 1997, 101(3):359-364.
35. Ruiz A., Puig S., Malvehy J., et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. JMed Genet 1999, 36(6):490-493.
36. Puig S., Malvehy J., Badenas C., et al. Role of the CDKN2A locus in patients with multiple primary melanomas. JClin Oncol 2005, 23(13):3043-3051. 10.1200/JCO.2005.08.034.
37. Larre Borges A., Cuéllar F., Puig-Butillé J.A., et al. CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 2009, 161(3):536-541.
38. Ward K.A., Lazovich D., Hordinsky M.K. Germline melanoma susceptibility and prognostic genes: a review of the literature. JAm Acad Dermatol 2012, 67(5):1055-1067. 10.1016/j.jaad.2012.02.042.
39. Bataille V., Kato B.S., Falchi M., et al. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence invivo. Cancer Epidemiol Biomarkers Prev 2007, 16(7):1499-1502.
40. Falchi M., Spector T.D., Perks U., et al. Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort. Hum Mol Genet 2006, 15(20):2975-2979.
41. Pujana M.A., Ruiz A., Badenas C., et al. Molecular characterization of a t(9;12)(p21;q13) balanced chromosome translocation in combination with integrative genomics analysis identifies C9orf14 as a candidate tumor-suppressor. Genes Chromosomes Cancer 2007, 46(2):155-162. 10.1002/gcc.20396.
42. Geller A.C., O'Riordan D.L., Oliveria S.A., et al. Overcoming obstacles to skin cancer examinations and prevention counseling for high-risk patients: results of a national survey of primary care physicians. JAm Board Fam Pract 2004, 17(6):416-423.
43. Hamidi R., Peng D., Cockburn M. Efficacy of skin self-examination for the early detection of melanoma. Int J Dermatol 2010, 49(2):126-134.
44. Stratigos A.J., Katsambas A.D. The value of screening in melanoma. Clin Dermatol 2009, 27(1):10-25.
45. Oliveria S.A., Chau D., Christos P.J., et al. Diagnostic accuracy of patients in performing skin self-examination and the impact of photography. Arch Dermatol 2004, 140:57-62.
46. Phelan D.L., Oliveria S.A., Halpern A.C. Patient experiences with photo books in monthly skin self-examinations. Dermatol Nurs 2005, 17(2):109-114.
47. Salerni G., Terán T., Puig S., et al. Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the International Dermoscopy Society. JEur Acad Dermatol Venereol 2013, 10.1111/jdv.12032.
48. Grob J.J., Bonerandi J.J. The "ugly duckling" sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998, 134(1):103-104.
49. Gachon J., Beaulieu P., Sei J.F., et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005, 141(4):434-438.
50. Mascaro J.M., Mascaro J.M. The dermatologist's position concerning nevi: a vision ranging from "the ugly duckling" to "little red riding hood". Arch Dermatol 1998, 134(11):1484-1485.
51. Argenziano G., Zalaudek I., Ferrara G., et al. Proposal of a new classification system for melanocytic naevi. Br J Dermatol 2007, 157(2):217-227.
52. Hofmann-Wellenhof R., Blum A., Wolf I.H., et al. Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). Clin Dermatol 2001, 20(3):255-258.
53. Blum A., Soyer H.P., Garbe C., et al. The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions. Br J Dermatol 2003, 149(6):1159-1164.
54. Fikrle T., Pizinger K. Dermatoscopic differences between atypical melanocytic naevi and thin malignant melanomas. Melanoma Res 2006, 16(1):45-50.
55. Arevalo A., Altamura D., Avramidis M., et al. The significance of eccentric and central hyperpigmentation, multifocal hyper/hypopigmentation, and the multicomponent pattern in melanocytic lesions lacking specific dermoscopic features of melanoma. Arch Dermatol 2008, 144(11):1440-1444.
56. Scope A., Dusza S.W., Halpern A.C., et al. The "ugly duckling" sign: agreement between observers. Arch Dermatol 2008, 144(1):58-64.
57. Roesch A., Burgdorf W., Stolz W., et al. Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness. Eur J Dermatol 2006, 16(5):479-493.
58. Lipoff J.B., Scope A., Dusza S.W., et al. Complex dermoscopic pattern: a potential risk marker for melanoma. Br J Dermatol 2008, 158(4):821-824.
59. Morales-Callaghan A.M., Castrodeza-Sanz J., Martínez-García G., et al. Correlation between clinical, dermatoscopic, and histopathologic variables in atypical melanocytic nevi. Actas Dermosifiliogr 2008, 99(5):380-389.
60. Zalaudek I., Docimo G., Argenziano G. Using dermoscopic criteria and patient-related factors forthe management of pigmented melanocytic nevi. Arch Dermatol 2009, 145(7):816-826.
61. Kittler H., Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch Dermatol 2001, 137(12):1590-1595.
62. Salerni G., Carrera C., Lovatto L., et al. Characterization of 1152 lesions excised over 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma. JAm Acad Dermatol 2012, 10.1016/j.jaad.2012.01.028.
63. Argenziano G., Mordente I., Ferrara G., et al. Dermoscopic monitoring of melanocytic skin lesions: clinical outcome and patient compliance vary according to follow-up protocols. Br J Dermatol 2008, 159(2):331-336.
64. Haenssle H.A., Krueger U., Vente C., et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. JInvest Dermatol 2006, 126(5):980-985.
65. Haenssle H.A., Vente C., Bertsch H.P., et al. Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev 2004, 13(2):133-138.
66. Haenssle H.A., Korpas B., Hansen-Hagge C., et al. Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk. JAm Acad Dermatol 2010, 62(5):785-793.
67. Haenssle H.A., Korpas B., Hansen-Hagge C., et al. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol 2010, 146(3):257-264.
68. Altamura D., Avramidis M., Menzies S.W. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol 2008, 144(4):502-506.
69. Gutkowicz-Krusin D., Elbaum M., Jacobs A., et al. Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind(TM) multispectral digital dermoscope. Melanoma Res 2000, 10(6):563-570.
70. Monheit G., Cognetta A.B., Ferris L., et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol 2011, 147:188-194.
71. Wilkinson B.A., Smallwood R.H., Keshtar A., et al. Electrical impedance spectroscopy and the diagnosis of bladder pathology: a pilot study. JUrol 2002, 168(4 Pt 1):1563-1567.
72. Zou Y., Guo Z. Areview of electrical impedance techniques for breast cancer detection. Med Eng Phys 2003, 25(2):79-90.
73. Brown B.H., Tidy J.A., Boston K., et al. Relation between tissue structure and imposed electrical current flow in cervical neoplasia. Lancet 2000, 355(9207):892-895.
74. Aberg P., Nicander I., Hansson J., et al. Skin cancer identification using multifrequency electrical impedance-a potential screening tool. IEEE Trans Biomed Eng 2004, 51:2097-2102. 10.1109/TBME.2004.836523.
75. Blad B., Baldetorp B. Impedance spectra of tumour tissue in comparison with normal tissue; a possible clinical application for electrical impedance tomography. Physiol Meas 1996, 17(Suppl 4):A105-A115. (0967-3334 (Print)).
76. Har-Shai Y., Glickman Y.A., Siller G., et al. Electrical impedance scanning for melanoma diagnosis: a validation study. Plast Reconstr Surg 2005, 116(3):782-790.
77. Wachsman W., Morhenn V., Palmer T., et al. Noninvasive genomic detection of melanoma. Br J Dermatol 2011, 164(4):797-806.